1
|
Arslan M, Haider A, Khurshid M, Abu Bakar SSU, Jani R, Masood F, Tahir T, Mitchell K, Panchagnula S, Mandair S. From Pixels to Pathology: Employing Computer Vision to Decode Chest Diseases in Medical Images. Cureus 2023; 15:e45587. [PMID: 37868395 PMCID: PMC10587792 DOI: 10.7759/cureus.45587] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/19/2023] [Indexed: 10/24/2023] Open
Abstract
Radiology has been a pioneer in the healthcare industry's digital transformation, incorporating digital imaging systems like picture archiving and communication system (PACS) and teleradiology over the past thirty years. This shift has reshaped radiology services, positioning the field at a crucial junction for potential evolution into an integrated diagnostic service through artificial intelligence and machine learning. These technologies offer advanced tools for radiology's transformation. The radiology community has advanced computer-aided diagnosis (CAD) tools using machine learning techniques, notably deep learning convolutional neural networks (CNNs), for medical image pattern recognition. However, the integration of CAD tools into clinical practice has been hindered by challenges in workflow integration, unclear business models, and limited clinical benefits, despite development dating back to the 1990s. This comprehensive review focuses on detecting chest-related diseases through techniques like chest X-rays (CXRs), magnetic resonance imaging (MRI), nuclear medicine, and computed tomography (CT) scans. It examines the utilization of computer-aided programs by researchers for disease detection, addressing key areas: the role of computer-aided programs in disease detection advancement, recent developments in MRI, CXR, radioactive tracers, and CT scans for chest disease identification, research gaps for more effective development, and the incorporation of machine learning programs into diagnostic tools.
Collapse
Affiliation(s)
- Muhammad Arslan
- Department of Emergency Medicine, Royal Infirmary of Edinburgh, National Health Service (NHS) Lothian, Edinburgh, GBR
| | - Ali Haider
- Department of Allied Health Sciences, The University of Lahore, Gujrat Campus, Gujrat, PAK
| | - Mohsin Khurshid
- Department of Microbiology, Government College University Faisalabad, Faisalabad, PAK
| | | | - Rutva Jani
- Department of Internal Medicine, C. U. Shah Medical College and Hospital, Gujarat, IND
| | - Fatima Masood
- Department of Internal Medicine, Gulf Medical University, Ajman, ARE
| | - Tuba Tahir
- Department of Business Administration, Iqra University, Karachi, PAK
| | - Kyle Mitchell
- Department of Internal Medicine, University of Science, Arts and Technology, Olveston, MSR
| | - Smruthi Panchagnula
- Department of Internal Medicine, Ganni Subbalakshmi Lakshmi (GSL) Medical College, Hyderabad, IND
| | - Satpreet Mandair
- Department of Internal Medicine, Medical University of the Americas, Charlestown, KNA
| |
Collapse
|
2
|
Fleming JS. The Use of Single Photon Emission Computed Tomography in Aerosol Medicine. J Aerosol Med Pulm Drug Deliv 2023; 36:44-53. [PMID: 36594940 DOI: 10.1089/jamp.2023.29077.jsf] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/04/2023] Open
Abstract
Imaging of radiolabeled aerosols provides useful in vivo data on both the initial site of deposition and its subsequent transport by mucociliary clearance and epithelial permeability. Single Photon Emission Computed Tomography (SPECT) uses a gamma camera with multiple rotating heads to produce three-dimensional (3D) images of inhaled radioaerosol labeled with technetium-99m. This enables total lung deposition and its 3D regional distribution to be quantified. Aligned 3D images of lung structure allow deposition data to be related to lung anatomy. Mucociliary clearance or epithelial permeability can be assessed from a time series of SPECT aerosol images. SPECT is slightly superior to planar imaging for measuring total lung deposition. However, it is more complex to use, and for studies where total lung deposition is the endpoint, planar imaging is recommended. However, SPECT has been shown to be clearly superior to planar imaging for assessing regional distribution of aerosol and is the method of choice for this purpose. It therefore has applications in studying the influence of regional deposition on clinical effectiveness and also in validating computer models of deposition. The inability to directly radiolabel drug molecules with 99mTc is a clear disadvantage of SPECT and limits its potential use for pharmacokinetic studies. SPECT provides a wealth of data on aerosol deposition, which has been relatively underused at present. Optimal methods of analyzing and interpreting the data need to be developed. SPECT can also, in principle, provide detailed information of mucociliary clearance and has the potential to significantly improve knowledge of this process and hence clarify the role of clearance as a biomarker.
Collapse
Affiliation(s)
- John S Fleming
- Department of Medical Physics, University Hospital Southampton NHS Foundation Trust, National Institute of Health Research Biomedical Research Centre, Southampton, United Kingdom
| |
Collapse
|
3
|
Matera MG, Calzetta L, Ora J, Rogliani P, Cazzola M. Pharmacokinetic/pharmacodynamic approaches to drug delivery design for inhalation drugs. Expert Opin Drug Deliv 2021; 18:891-906. [PMID: 33412922 DOI: 10.1080/17425247.2021.1873271] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Abstract
Introduction: Inhaled drugs are important in the treatment of many lung pathologies, but to be therapeutically effective they must reach unbound concentrations at their effect site in the lung that are adequate to interact with their pharmacodynamic properties (PD) and exert the pharmacological action over an appropriate dosing interval. Therefore, the evaluation of pharmacokinetic (PK)/PD relationship is critical to predict their possible therapeutic effect.Areas covered: We review the approaches used to assess the PK/PD relationship of the major classes of inhaled drugs that are prescribed to treat pulmonary pathologies.Expert opinion: There are still great difficulties in producing data on lung concentrations of inhaled drugs and interpreting them as to their ability to induce the desired therapeutic action. The structural complexity of the lungs, the multiplicity of processes involved simultaneously and the physical interactions between the lungs and drug make any PK/PD approach to drug delivery design for inhalation medications extremely challenging. New approaches/methods are increasing our understanding about what happens to inhaled drugs, but they are still not ready for regulatory purposes. Therefore, we must still rely on plasma concentrations based on the axiom that they reflect both the extent and the pattern of deposition within the lungs.
Collapse
Affiliation(s)
- Maria Gabriella Matera
- Unit of Pharmacology, Dept. Experimental Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy
| | - Luigino Calzetta
- Unit of Respiratory Disease and Lung Function, Dept. Medicine and Surgery, University of Parma, Parma, Italy
| | - Josuel Ora
- Unit of Respiratory Medicine, Dept. Experimental Medicine, University of Rome "Tor Vergata", Rome, Italy
| | - Paola Rogliani
- Unit of Respiratory Medicine, Dept. Experimental Medicine, University of Rome "Tor Vergata", Rome, Italy
| | - Mario Cazzola
- Unit of Respiratory Medicine, Dept. Experimental Medicine, University of Rome "Tor Vergata", Rome, Italy
| |
Collapse
|
4
|
Current Applications for Nuclear Medicine Imaging in Pulmonary Disease. CURRENT PULMONOLOGY REPORTS 2020; 9:82-95. [PMID: 32837866 PMCID: PMC7374080 DOI: 10.1007/s13665-020-00251-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
Abstract
Purpose of Review The main goal of the article is to familiarize the reader with commonly and uncommonly used nuclear medicine procedures that can significantly contribute to improved patient care. The article presents examples of specific modality utilization in the chest including assessment of lung ventilation and perfusion, imaging options for broad range of infectious and inflammatory processes, and selected aspects of oncologic imaging. In addition, rapidly developing new techniques utilizing molecular imaging are discussed. Recent Findings The article describes nuclear medicine imaging modalities including gamma camera, SPECT, PET, and hybrid imaging (SPECT/CT, PET/CT, and PET/MR) in the context of established and emerging clinical applications. Areas of potential future development in nuclear medicine are discussed with emphasis on molecular imaging and implementation of new targeted tracers used in diagnostics and therapeutics (theranostics). Summary Nuclear medicine and molecular imaging provide many unique and novel options for the diagnosis and treatment of pulmonary diseases. This article reviews current applications for nuclear medicine and molecular imaging and selected future applications for radiopharmaceuticals and targeted molecular imaging techniques.
Collapse
|
5
|
Dentice RL, Elkins MR, Verschuer J, Eberl S, Dwyer G, Bye PTP. Side lying during nebulisation can significantly improve apical deposition in healthy adults and adults with mild cystic fibrosis lung disease: a randomised crossover trial. BMC Pulm Med 2019; 19:128. [PMID: 31311524 PMCID: PMC6636004 DOI: 10.1186/s12890-019-0886-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2019] [Accepted: 06/25/2019] [Indexed: 11/17/2022] Open
Abstract
Background In people with and without Cystic Fibrosis (CF), does side lying during nebulisation change: the proportion of the dose loaded in the nebuliser that is deposited in the lungs; the uniformity of deposition throughout the lungs; or the apical drug density as a percentage of the drug density in the remaining lung? Do these effects differ depending on the degree of lung disease present? Methods A randomised crossover trial with concealed allocation, intention-to-treat analysis and blinded assessors, involving 39 adults: 13 healthy, 13 with mild CF lung disease (FEV1 > 80%pred), and 13 with more advanced CF lung disease (FEV1 < 80%pred). In random order, 4 mL of nebulised radioaerosol was inhaled in upright sitting and in alternate right and left side lying at 2-min intervals, for 20 min. Results Compared to sitting upright, lung deposition and the uniformity of deposition were not significantly altered by side lying in any of the three groups. In sitting, the density of the deposition was significantly less in the apical regions than in the rest of the lung in all participants. Side lying significantly improved apical deposition in healthy adults (MD, 13%; 95% CI, 7 to 19), and in minimal CF lung disease (MD, 4%; 95% CI, 1 to 7) but not in advanced disease (MD, 4%; 95% CI, − 2 to 9). Conclusion Alternating between right and left side lying during nebulisation significantly improves apical deposition in healthy adults and in adults with mild CF lung disease, without substantial detriment to overall deposition. Trial registration ACTRN12611000674932 (Healthy), ACTRN12611000672954 (CF) Retrospectively registered 4/7/2011. Electronic supplementary material The online version of this article (10.1186/s12890-019-0886-7) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Ruth L Dentice
- Physiotherapy Department, Royal Prince Alfred Hospital, Sydney, Australia.
| | - Mark R Elkins
- Centre for Education & Workforce Development, Sydney Local Health District, Sydney, Australia.,Sydney Medical School, University of Sydney, Sydney, Australia
| | - Jordan Verschuer
- Department of Molecular Imaging, Royal Prince Alfred Hospital, Sydney, Australia
| | - Stefan Eberl
- Department of Molecular Imaging, Royal Prince Alfred Hospital, Sydney, Australia
| | - Genevieve Dwyer
- Physiotherapy Program, Western Sydney University, Sydney, Australia.
| | - Peter T P Bye
- Sydney Medical School, University of Sydney, Sydney, Australia.,Department of Respiratory Medicine, Royal Prince Alfred Hospital, Sydney, Australia
| |
Collapse
|
6
|
Zinellu E, Piras B, Ruzittu GGM, Fois SS, Fois AG, Pirina P. Recent Advances in Inflammation and Treatment of Small Airways in Asthma. Int J Mol Sci 2019; 20:ijms20112617. [PMID: 31141956 PMCID: PMC6601314 DOI: 10.3390/ijms20112617] [Citation(s) in RCA: 20] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2019] [Revised: 05/16/2019] [Accepted: 05/27/2019] [Indexed: 12/14/2022] Open
Abstract
Small airways were historically considered to be almost irrelevant in the development and control of pulmonary chronic diseases but, as a matter of fact, in the past few years we have learned that they are not so "silent". Asthma is still a worldwide health issue due to the great share of patients being far from optimal management. Several studies have shown that the deeper lung inflammation plays a critical role in asthma pathogenesis, mostly in these not well-controlled subjects. Therefore, assessing the degree of small airways inflammation and impairment appears to be a pivotal step in the asthmatic patient's management. It is now possible to evaluate them through direct and indirect measurements, even if some obstacles still affect their clinical application. The success of any treatment obviously depends on several factors but reaching the deeper lung has become a priority and, for inhaled drugs, this is strictly connected to the molecule's size. The aim of the present review is to summarize the recent evidence concerning the small airway involvement in asthma, its physiopathological characteristics and how it can be evaluated in order to undertake a personalized pharmacological treatment and achieve a better disease control.
Collapse
Affiliation(s)
- Elisabetta Zinellu
- Respiratory Unit, Azienda Ospedaliero Universitaria (AOU), V.le San Pietro, 07100 Sassari, Italy.
| | - Barbara Piras
- Respiratory Unit, Department of Medical, Surgical and Experimental Sciences, University of Sassari, V.le San Pietro, 07100 Sassari, Italy.
| | - Giulia G M Ruzittu
- Respiratory Unit, Department of Medical, Surgical and Experimental Sciences, University of Sassari, V.le San Pietro, 07100 Sassari, Italy.
| | - Sara S Fois
- Respiratory Unit, Department of Medical, Surgical and Experimental Sciences, University of Sassari, V.le San Pietro, 07100 Sassari, Italy.
| | - Alessandro G Fois
- Respiratory Unit, Department of Medical, Surgical and Experimental Sciences, University of Sassari, V.le San Pietro, 07100 Sassari, Italy.
| | - Pietro Pirina
- Respiratory Unit, Azienda Ospedaliero Universitaria (AOU), V.le San Pietro, 07100 Sassari, Italy.
- Respiratory Unit, Department of Medical, Surgical and Experimental Sciences, University of Sassari, V.le San Pietro, 07100 Sassari, Italy.
| |
Collapse
|
7
|
Khoubnasabjafari M, Rahimpour E, Samini M, Jouyban-Gharamaleki V, Chen L, Chen D, Chan HK, Jouyban A. A new hypothesis to investigate bioequivalence of pharmaceutical inhalation products. ACTA ACUST UNITED AC 2019; 27:517-524. [PMID: 30847847 DOI: 10.1007/s40199-019-00250-x] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2018] [Accepted: 02/13/2019] [Indexed: 10/27/2022]
Abstract
BACKGROUND This short communication reports a new hypothesis regarding bioequivalence of inhalation products which can potentially provide a reliable means to compare pharmaceutical aerosol formulations and inhalers. METHODS Available methods regarding the bioequivalence studies, inhaled drugs and advantages of exhaled breath condensate (EBC) samples were reviewed to develop this hypothesis. RESULTS It is postulated that two inhalation products providing the same drug concentrations in airway lining fluid (ALF) could be considered bioequivalent. The use of EBC tests which reflect ALF composition can be recommended as an alternative to current testing methods for consideration of bioequivalence. CONCLUSION The methods based on EBC analysis can potentially be applied to bioequivalence study of inhalation products and could reflect drug concentration in ALF. However, experimental studies would be necessary to support or refute this hypothesis on the novel application of EBC to bioequivalence in the future. Graphical abstract In vitro (cascade impactor) and In vivo (EBC concentration) corrolation for inhaled drugs.
Collapse
Affiliation(s)
- Maryam Khoubnasabjafari
- Tuberculosis and Lung Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Elaheh Rahimpour
- Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Morteza Samini
- Research and Development Department, Jaber Ebne Hayyan Pharmaceutical Co., Tehran, Iran
| | - Vahid Jouyban-Gharamaleki
- Liver and Gastrointestinal Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.,Kimia Idea Pardaz Azarbayjan (KIPA) Science Based Company, Tabriz University of Medical Sciences, Tabriz, Iran
| | - Lan Chen
- Hangzhou Chance Pharmaceuticals, Hangzhou, China.,University of Shanghai for Science and Technology, Shanghai, China
| | - Donghao Chen
- Hangzhou Chance Pharmaceuticals, Hangzhou, China
| | - Hak-Kim Chan
- Advanced Drug Delivery Group, School of Pharmacy, University of Sydney, Sydney, NSW 2006, Australia
| | - Abolghasem Jouyban
- Pharmaceutical Analysis Research Center and Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran.
| |
Collapse
|
8
|
Abstract
Environmental and occupational exposure to particulate aerosols is known to have negative health effects. However little is known about how these aerosols trigger the development of pathophysiological mechanisms in the body or the fate of ultrafine particles in the lungs after inhalation. The development of aerosols of different origin that can be labeled to a large variety with radionuclides compatible with clinical gamma camera systems opens the possibility of using lung scintigraphy imaging to study these causalities in detail. Lung scintigraphy (planar or SPECT) allows regional mapping of the deposition of the aerosol in the lungs and the dynamic assessment of particle clearance and translocation from the healthy and affected human lungs. In this paper, we will review the unique features of lung scintigraphy applied to aerosol clearance studies in humans.
Collapse
Affiliation(s)
- Alejandro Sanchez-Crespo
- Department of Medical Radiation Physics and Nuclear Medicine, Karolinska University Hospital, Stockholm, Sweden; Department of Oncology-pathology. Karolinska Institutet, Stockholm, Sweden.
| |
Collapse
|
9
|
Kourmatzis A, Cheng S, Chan HK. Airway geometry, airway flow, and particle measurement methods: implications on pulmonary drug delivery. Expert Opin Drug Deliv 2017; 15:271-282. [DOI: 10.1080/17425247.2018.1406917] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Affiliation(s)
- A. Kourmatzis
- School of Aerospace, Mechanical and Mechatronic Engineering, The University of Sydney, Sydney, Australia
| | - S. Cheng
- Department of Engineering, Macquarie University, Sydney, Australia
| | - H.-K. Chan
- Advanced Drug Delivery Group, Faculty of Pharmacy, The University of Sydney, Sydney, Australia
| |
Collapse
|
10
|
Mayers I, Bhutani M. Considerations in establishing bioequivalence of inhaled compounds. Expert Opin Drug Deliv 2017; 15:153-162. [PMID: 28918665 DOI: 10.1080/17425247.2018.1381084] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
INTRODUCTION Generic inhalers are often perceived as inferior to their branded counterparts; however, they are safe and effective if they can meet the regulatory requirements. The approach to assess bioequivalence (BE) in oral dosage form products is not sufficient to address the complexities of inhalational products (e.g., patient-device interface); hence, more considerations are needed and caution should be applied in determining BE of inhaled compounds. AREAS COVERED This review outlines the evaluation process for generic inhalers, explores the regulatory approaches in BE assessment, and highlights the considerations and challenges in the current in vitro and in vivo approaches (lung deposition, pharmacokinetic, pharmacodynamic/clinical studies, and patient-device interface) for establishing BE of inhaled compounds. EXPERT OPINION The ultimate goals in this field are to establish uniformity in the regulatory approaches to speed the drug submission process in different regions, clear physicians' misconception of generic inhalers, and have meaningful clinical endpoints such as improvement in patient quality of life when compared to placebo and brand name drugs. As inhalational drugs become more common for other indications such as antibiotics, the technologies developed for inhaled compounds in the treatment of chronic pulmonary diseases may be extrapolated to these other agents.
Collapse
Affiliation(s)
- Irvin Mayers
- a Division of Pulmonary Medicine, Department of Medicine , University of Alberta , Edmonton , AB , Canada
| | - Mohit Bhutani
- a Division of Pulmonary Medicine, Department of Medicine , University of Alberta , Edmonton , AB , Canada
| |
Collapse
|
11
|
Mayers I, Bhutani M. Regulatory Approaches and Considerations in Establishing Bioequivalence of Inhaled Compounds. J Aerosol Med Pulm Drug Deliv 2017; 31:18-24. [PMID: 28708443 DOI: 10.1089/jamp.2017.1398] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023] Open
Abstract
To be considered bioequivalent to their branded counterparts, generic drugs must meet the standards for bioequivalence (BE) described by the regulatory agencies. While BE of generic inhalational drugs can be evaluated using a similar approach as that for oral dosage from products or drugs that are delivered systemically, the approach is insufficient to address the complexities of inhalational products (e.g., localized site of action, device-patient interface). Therefore, more considerations are needed and caution should be applied when evaluating BE of inhaled compounds. The purpose of this review is to highlight the considerations and challenges in establishing BE of inhaled compounds by (1) outlining the current regulatory approaches (from Health Canada, the U.S. Food and Drug Administration, and the European Medicines Agency) to assess BE for subsequent entry inhaled products (SEIPs) and (2) reviewing the literature pertaining to testing considerations of SEIPs to establish BE.
Collapse
Affiliation(s)
- Irvin Mayers
- Division of Pulmonary Medicine, Department of Medicine, Faculty of Medicine and Dentistry, University of Alberta , Edmonton, Canada
| | - Mohit Bhutani
- Division of Pulmonary Medicine, Department of Medicine, Faculty of Medicine and Dentistry, University of Alberta , Edmonton, Canada
| |
Collapse
|
12
|
Ilic V, Dunet V, Le Pape A, Buchs M, Kosinski M, Bischof Delaloye A, Gerber S, Prior JO. SPECT/CT study of bronchial deposition of inhaled particles. A human aerosol vaccination model against HPV. Nuklearmedizin 2016; 55:203-8. [PMID: 27440125 DOI: 10.3413/nukmed-0811-16-03] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2016] [Accepted: 06/28/2016] [Indexed: 02/01/2023]
Abstract
AIMS Vaccination by aerosol inhalation can be used to efficiently deliver antigen against HPV to mucosal tissue, which is particularly useful in developing countries (simplicity of administration, costs, no need for cold chain). For optimal immunological response, vaccine particles should preferentially be delivered to proximal bronchial airways. We aimed at quantifying the deposition of inhaled particles in central airways and peripheral lung, and to assess administration biosafety. Participants, methods: 20 healthy volunteers (13W/7M, aged 24±4y) performed a 10-min free-breathing inhalation of (99m)Tc-stannous chloride colloid aerosol (450 MBq) in a buffer solution without vaccinal particles using an ultrasonic nebulizer (mass median aerodynamic diameter 4.2 μm) and a double mask inside a biosafety cabinet dedicated to assess environmental particle release. SPECT/CT and whole-body planar scintigraphy were acquired to determine whole-body and regional C/P distribution ratio (central-to-peripheral pulmonary deposition counts). Using a phantom, SPECT sensitivity was calibrated to obtain absolute pulmonary activity deposited by inhalation. RESULTS All participants successfully performed the inhalation that was well tolerated (no change in pulmonary peak expiratory flow rate, p = 0.9). It was environmentally safe (no activity released in the biosafety filter.) 1.3±0.6% (range 0.4-2.6%) of the total nebulizer activity was deposited in the lungs with a C/P distribution ratio of 0.40±0.20 (range 0.15-1.14). CONCLUSION Quantification and regional distribution of inhaled particles in an aerosolized vaccine model is possible using radioactive particles. This will allow optimizing deposition parameters and determining the particles charge for active-particles vaccination.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | - John O Prior
- Prof. John O. Prior, PhD MD, Department of Nuclear Medicine and Molecular Imaging, Lausanne University Hospital, Rue du Bugnon 46, 1011 Lausanne, Switzerland, Tel. +41/21/314 43-48, Fax -49,
| |
Collapse
|
13
|
Youngren-Ortiz SR, Gandhi NS, España-Serrano L, Chougule MB. Aerosol Delivery of siRNA to the Lungs. Part 1: Rationale for Gene Delivery Systems. KONA : POWDER SCIENCE AND TECHNOLOGY IN JAPAN 2016; 33:63-85. [PMID: 27081214 PMCID: PMC4829385 DOI: 10.14356/kona.2016014] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/05/2023]
Abstract
This article reviews the pulmonary route of administration, aerosol delivery devices, characterization of pulmonary drug delivery systems, and discusses the rationale for inhaled delivery of siRNA. Diseases with known protein malfunctions may be mitigated through the use of siRNA therapeutics. The inhalation route of administration provides local delivery of siRNA therapeutics for the treatment of various pulmonary diseases, however barriers to pulmonary delivery and intracellular delivery of siRNA exists. siRNA loaded nanocarriers can be used to overcome the barriers associated with the pulmonary route, such as anatomical barriers, mucociliary clearance, and alveolar macrophage clearance. Apart from naked siRNA aerosol delivery, previously studied siRNA carrier systems comprise of lipidic, polymeric, peptide, or inorganic origin. Such siRNA delivery systems formulated as aerosols can be successfully delivered via an inhaler or nebulizer to the pulmonary region. Preclinical animal investigations of inhaled siRNA therapeutics rely on intratracheal and intranasal siRNA and siRNA nanocarrier delivery. Aerosolized siRNA delivery systems may be characterized using in vitro techniques, such as dissolution test, inertial cascade impaction, delivered dose uniformity assay, laser diffraction, and laser Doppler velocimetry. The ex vivo techniques used to characterize pulmonary administered formulations include the isolated perfused lung model. In vivo techniques like gamma scintigraphy, 3D SPECT, PET, MRI, fluorescence imaging and pharmacokinetic/pharmacodynamics analysis may be used for evaluation of aerosolized siRNA delivery systems. The use of inhalable siRNA delivery systems encounters barriers to their delivery, however overcoming the barriers while formulating a safe and effective delivery system will offer unique advances to the field of inhaled medicine.
Collapse
Affiliation(s)
- Susanne R. Youngren-Ortiz
- Department of Pharmaceutical Sciences, The Daniel K. Inouye College of Pharmacy, University of Hawaii at Hilo, 200 West Kawili Street, Hilo, Hawaii 96720, USA
| | - Nishant S. Gandhi
- Department of Pharmaceutical Sciences, The Daniel K. Inouye College of Pharmacy, University of Hawaii at Hilo, 200 West Kawili Street, Hilo, Hawaii 96720, USA
| | - Laura España-Serrano
- Department of Pharmaceutical Sciences, The Daniel K. Inouye College of Pharmacy, University of Hawaii at Hilo, 200 West Kawili Street, Hilo, Hawaii 96720, USA
| | - Mahavir B. Chougule
- Department of Pharmaceutical Sciences, The Daniel K. Inouye College of Pharmacy, University of Hawaii at Hilo, 200 West Kawili Street, Hilo, Hawaii 96720, USA
- Natural Products and Experimental Therapeutics Program, University of Hawaii Cancer Center, University of Hawaii at Manoa, Honolulu, Hawaii 96813, USA
| |
Collapse
|
14
|
Norberg P, Olsson A, Alm Carlsson G, Sandborg M, Gustafsson A. Optimisation of quantitative lung SPECT applied to mild COPD: a software phantom simulation study. EJNMMI Res 2015; 5:16. [PMID: 25853022 PMCID: PMC4385278 DOI: 10.1186/s13550-015-0086-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2014] [Accepted: 02/16/2015] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND The amount of inhomogeneities in a (99m)Tc Technegas single-photon emission computed tomography (SPECT) lung image, caused by reduced ventilation in lung regions affected by chronic obstructive pulmonary disease (COPD), is correlated to disease advancement. A quantitative analysis method, the CVT method, measuring these inhomogeneities was proposed in earlier work. To detect mild COPD, which is a difficult task, optimised parameter values are needed. METHODS In this work, the CVT method was optimised with respect to the parameter values of acquisition, reconstruction and analysis. The ordered subset expectation maximisation (OSEM) algorithm was used for reconstructing the lung SPECT images. As a first step towards clinical application of the CVT method in detecting mild COPD, this study was based on simulated SPECT images of an advanced anthropomorphic lung software phantom including respiratory and cardiac motion, where the mild COPD lung had an overall ventilation reduction of 5%. RESULTS The best separation between healthy and mild COPD lung images as determined using the CVT measure of ventilation inhomogeneity and 125 MBq (99m)Tc was obtained using a low-energy high-resolution collimator (LEHR) and a power 6 Butterworth post-filter with a cutoff frequency of 0.6 to 0.7 cm(-1). Sixty-four reconstruction updates and a small kernel size should be used when the whole lung is analysed, and for the reduced lung a greater number of updates and a larger kernel size are needed. CONCLUSIONS A LEHR collimator and 125 (99m)Tc MBq together with an optimal combination of cutoff frequency, number of updates and kernel size, gave the best result. Suboptimal selections of either cutoff frequency, number of updates and kernel size will reduce the imaging system's ability to detect mild COPD in the lung phantom.
Collapse
Affiliation(s)
- Pernilla Norberg
- Medical Radiation Physics, Department of Medical and Health Sciences, Linköping University, Linköping, 581 83 Sweden ; Center for Medical Image Science and Visualization (CMIV), Linköping University, Linköping, 581 83 Sweden
| | - Anna Olsson
- Medical Radiation Physics, Department of Medical and Health Sciences, Linköping University, Linköping, 581 83 Sweden ; Center for Medical Image Science and Visualization (CMIV), Linköping University, Linköping, 581 83 Sweden ; Clinical Physiology, Department of Medical and Health Sciences, Linköping University, Linköping, 581 83 Sweden
| | - Gudrun Alm Carlsson
- Medical Radiation Physics, Department of Medical and Health Sciences, Linköping University, Linköping, 581 83 Sweden ; Center for Medical Image Science and Visualization (CMIV), Linköping University, Linköping, 581 83 Sweden
| | - Michael Sandborg
- Medical Radiation Physics, Department of Medical and Health Sciences, Linköping University, Linköping, 581 83 Sweden ; Center for Medical Image Science and Visualization (CMIV), Linköping University, Linköping, 581 83 Sweden
| | - Agnetha Gustafsson
- Department of Medical Physics, Karolinska University Hospital, Huddinge, Stockholm 141 86 Sweden
| |
Collapse
|
15
|
Norberg P, Persson HL, Schmekel B, Carlsson GA, Wahlin K, Sandborg M, Gustafsson A. Does quantitative lung SPECT detect lung abnormalities earlier than lung function tests? Results of a pilot study. EJNMMI Res 2014; 4:39. [PMID: 26055938 PMCID: PMC4884006 DOI: 10.1186/s13550-014-0039-1] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/24/2014] [Accepted: 07/02/2014] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND Heterogeneous ventilation in lungs of individuals with allergies, cigarette smokers, asthmatics and chronic obstructive pulmonary disease (COPD) patients has been demonstrated using imaging modalities such as positron emission tomography (PET), magnetic resonance imaging (MRI) and single-photon emission computed tomography (SPECT). These individuals suffer from narrow and/or closed airways to various extents. By calculating regional heterogeneity in lung ventilation SPECT images as the coefficient of variation (CV) in small elements of the lung, heterogeneity maps and CV-density curves can be generated and used to quantitatively measure heterogeneity. This work explores the potential to use such measurements to detect mild ventilation heterogeneities in lung-healthy subjects. METHOD Fourteen healthy subjects without documented lung disease or respiratory symptoms, and two patients with documented airway disease, inhaled on average approximately 90 MBq (99m)Tc-Technegas immediately prior to the 20-min SPECT acquisition. Variation in activity uptake between subjects was compensated for in resulting CV values. The area under the compensated CV density curve (AUC), for CV values greater than a threshold value CVT, AUC(CV > CVT), was used as the measure of ventilation heterogeneity. RESULTS Patients with lung function abnormalities, according to lung function tests, generated higher AUC(CV > 20%) values compared to healthy subjects (p = 0.006). Strong linear correlations with the AUC(CV > 20%) values were found for age (p = 0.006) and height (p = 0.001). These demonstrated that ventilation heterogeneities increased with age and that they depend on lung size. Strong linear correlations were found for the lung function value related to indices of airway closure/air trapping, residual volume/total lung capacity (RV/TLC; p = 0.009), and diffusion capacity of the lung for carbon monoxide adjusted for haemoglobin concentration in the blood (DLCOc; p = 0.009), a value partly related to supposed ventilation/perfusion mismatch. These findings support the association between conventional lung function tests and the AUC(CV > 20%) value. CONCLUSIONS Among the healthy subjects, there is a group with increased AUC(CV > 20%) values, but with normal lung function tests, which implies that it might be possible to differentiate ventilation heterogeneities earlier in a disease process than by lung function tests.
Collapse
Affiliation(s)
- Pernilla Norberg
- />Medical Radiation Physics, County Council of Östergötland, Linköping, 581 85 Sweden
- />Center for Medical Image Science and Visualization (CMIV), Linköping University, Linköping, 581 83 Sweden
- />Department of Medical and Health Sciences, Linköping University, Linköping, 581 83 Sweden
| | - Hans Lennart Persson
- />Department of Respiratory Medicine and Department of Medical and Health Sciences, Linköping University, Linköping, 581 83 Sweden
| | - Birgitta Schmekel
- />Department of Clinical Physiology and Department of Medical and Health Sciences, Linköping University, Linköping, 581 83 Sweden
| | - Gudrun Alm Carlsson
- />Center for Medical Image Science and Visualization (CMIV), Linköping University, Linköping, 581 83 Sweden
- />Department of Medical and Health Sciences, Linköping University, Linköping, 581 83 Sweden
| | - Karl Wahlin
- />Department of Computer and Information Science, Linköping University, Linköping, 581 83 Sweden
| | - Michael Sandborg
- />Center for Medical Image Science and Visualization (CMIV), Linköping University, Linköping, 581 83 Sweden
- />Department of Medical and Health Sciences, Linköping University, Linköping, 581 83 Sweden
| | - Agnetha Gustafsson
- />Department of Medical Physics, Karolinska University Hospital, Huddinge, Stockholm 141 86 Sweden
| |
Collapse
|
16
|
Pulmonary drug delivery by powder aerosols. J Control Release 2014; 193:228-40. [DOI: 10.1016/j.jconrel.2014.04.055] [Citation(s) in RCA: 128] [Impact Index Per Article: 12.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2014] [Revised: 04/27/2014] [Accepted: 04/29/2014] [Indexed: 12/24/2022]
|
17
|
McNulty W, Usmani OS. Techniques of assessing small airways dysfunction. Eur Clin Respir J 2014; 1:25898. [PMID: 26557240 PMCID: PMC4629724 DOI: 10.3402/ecrj.v1.25898] [Citation(s) in RCA: 138] [Impact Index Per Article: 13.8] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2014] [Accepted: 09/11/2014] [Indexed: 11/17/2022] Open
Abstract
The small airways are defined as those less than 2 mm in diameter. They are a major site of pathology in many lung diseases, not least chronic obstructive pulmonary disease (COPD) and asthma. The small airways are frequently involved early in the course of these diseases, with significant pathology demonstrable often before the onset of symptoms or changes in spirometry and imaging. Despite their importance, they have proven relatively difficult to study. This is in part due to their relative inaccessibility to biopsy and their small size which makes their imaging difficult. Traditional lung function tests may only become abnormal once there is a significant burden of disease within them. This has led to the term 'the quiet zone' of the lung. In recent years, more specialised tests have been developed which may detect these changes earlier, perhaps offering the possibility of earlier diagnosis and intervention. These tests are now moving from the realms of clinical research laboratories into routine clinical practice and are increasingly useful in the diagnosis and monitoring of respiratory diseases. This article gives an overview of small airways physiology and some of the routine and more advanced tests of airway function.
Collapse
Affiliation(s)
- William McNulty
- National Heart and lung Institute, Imperial College London and Royal Brompton Hospital, London, UK
| | | |
Collapse
|
18
|
Löndahl J, Möller W, Pagels JH, Kreyling WG, Swietlicki E, Schmid O. Measurement techniques for respiratory tract deposition of airborne nanoparticles: a critical review. J Aerosol Med Pulm Drug Deliv 2014; 27:229-54. [PMID: 24151837 PMCID: PMC4120654 DOI: 10.1089/jamp.2013.1044] [Citation(s) in RCA: 87] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2013] [Accepted: 09/15/2013] [Indexed: 12/14/2022] Open
Abstract
Determination of the respiratory tract deposition of airborne particles is critical for risk assessment of air pollution, inhaled drug delivery, and understanding of respiratory disease. With the advent of nanotechnology, there has been an increasing interest in the measurement of pulmonary deposition of nanoparticles because of their unique properties in inhalation toxicology and medicine. Over the last century, around 50 studies have presented experimental data on lung deposition of nanoparticles (typical diameter≤100 nm, but here≤300 nm). These data show a considerable variability, partly due to differences in the applied methodologies. In this study, we review the experimental techniques for measuring respiratory tract deposition of nano-sized particles, analyze critical experimental design aspects causing measurement uncertainties, and suggest methodologies for future studies. It is shown that, although particle detection techniques have developed with time, the overall methodology in respiratory tract deposition experiments has not seen similar progress. Available experience from previous research has often not been incorporated, and some methodological design aspects that were overlooked in 30-70% of all studies may have biased the experimental data. This has contributed to a significant uncertainty on the absolute value of the lung deposition fraction of nanoparticles. We estimate the impact of the design aspects on obtained data, discuss solutions to minimize errors, and highlight gaps in the available experimental set of data.
Collapse
Affiliation(s)
- Jakob Löndahl
- Ergonomics and Aerosol Technology (EAT), Lund University, SE-221 00 Lund, Sweden
| | - Winfried Möller
- Comprehensive Pneumology Center, Institute of Lung Biology and Disease, Helmholtz Zentrum München, 85764 Neuherberg, Germany
| | - Joakim H. Pagels
- Ergonomics and Aerosol Technology (EAT), Lund University, SE-221 00 Lund, Sweden
| | - Wolfgang G. Kreyling
- Comprehensive Pneumology Center, Institute of Lung Biology and Disease, Helmholtz Zentrum München, 85764 Neuherberg, Germany
| | | | - Otmar Schmid
- Comprehensive Pneumology Center, Institute of Lung Biology and Disease, Helmholtz Zentrum München, 85764 Neuherberg, Germany
| |
Collapse
|
19
|
Leclerc L, Pourchez J, Prevot N, Vecellio L, Le Guellec S, Cottier M, Durand M. Assessing sinus aerosol deposition: benefits of SPECT-CT imaging. Int J Pharm 2013; 462:135-41. [PMID: 24374606 DOI: 10.1016/j.ijpharm.2013.12.032] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2013] [Revised: 12/12/2013] [Accepted: 12/17/2013] [Indexed: 11/30/2022]
Abstract
PURPOSE Aerosol inhalation therapy is one of the methods to treat rhinosinusitis. However the topical drug delivery to the posterior nose and paranasal sinuses shows only limited efficiency. A precise sinusal targeting remains a main challenge for aerosol treatment of sinus disorders. This paper proposes a comparative study of the nasal deposition patterns of micron and submicron particles using planar gamma-scintigraphy imaging vs. a new 3-dimensional (3D) imaging approach based on SPECT-CT measurements. METHODS Radiolabelled nebulizations have been performed on a plastinated model of human nasal cast coupled with a respiratory pump. First, the benefits provided by SPECT-CT imaging were compared with 2D gamma-scintigraphy and radioactive quantification of maxillary sinus lavage as reference for the sonic 2.8 μm aerosol sinusal deposition. Then, the impact on nasal deposition of various airborne particle sizes was assessed. RESULTS The 2D methodology overestimates aerosol deposition in the maxillary sinuses by a factor 9 whereas the 3D methodology is in agreement with the maxillary sinus lavage reference methodology. Then with the SPECT-CT approach we highlighted that the higher particle size was mainly deposited in the central nasal cavity contrary to the submicron aerosol particles (33.8 ± 0.6% of total deposition for the 2.8 μm particles vs. 1 ± 0.3% for the 230 nm particles). CONCLUSION Benefits of SPECT/CT for the assessment of radiolabelled aerosol deposition in rhinology are clearly demonstrated. This 3D methodology should be preferentially used for scintigraphic imaging of sinusal deposition in Human.
Collapse
Affiliation(s)
- Lara Leclerc
- Université Jean Monnet, LINA EA 4624, Université de Lyon, F-42023 Saint-Etienne, France; Ecole Nationale Supérieure des Mines, CIS-EMSE, LINA EA 4624, F-42023 Saint-Etienne, France; SFR IFRESIS, F-42023 Saint-Etienne, France.
| | - Jérémie Pourchez
- Ecole Nationale Supérieure des Mines, CIS-EMSE, LINA EA 4624, F-42023 Saint-Etienne, France; SFR IFRESIS, F-42023 Saint-Etienne, France
| | - Nathalie Prevot
- Université Jean Monnet, LINA EA 4624, Université de Lyon, F-42023 Saint-Etienne, France; SFR IFRESIS, F-42023 Saint-Etienne, France; CHU de Saint-Etienne, Nuclear Medicine Department, F-42055 Saint-Etienne, France
| | - Laurent Vecellio
- Centre d'Etudes des Pathologies Respiratoires INSERM U1100/EA 6305, Faculté de Médecine, Université François Rabelais, Tours, France; DTF Aerodrug, Faculté de Médecine, Université François Rabelais, Tours, France
| | - Sandrine Le Guellec
- Centre d'Etudes des Pathologies Respiratoires INSERM U1100/EA 6305, Faculté de Médecine, Université François Rabelais, Tours, France; DTF Aerodrug, Faculté de Médecine, Université François Rabelais, Tours, France
| | - Michèle Cottier
- Université Jean Monnet, LINA EA 4624, Université de Lyon, F-42023 Saint-Etienne, France; SFR IFRESIS, F-42023 Saint-Etienne, France
| | - Marc Durand
- Université Jean Monnet, LINA EA 4624, Université de Lyon, F-42023 Saint-Etienne, France; SFR IFRESIS, F-42023 Saint-Etienne, France; Centre Hospitalier Emile Roux, ENT Department, F-43012 Le Puy en Velay, France
| |
Collapse
|
20
|
Conway J, Fleming J, Bennett M, Havelock T. The co-imaging of gamma camera measurements of aerosol deposition and respiratory anatomy. J Aerosol Med Pulm Drug Deliv 2013; 26:123-30. [PMID: 23517170 DOI: 10.1089/jamp.2011.0960] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
The use of gamma camera imaging following the inhalation of a radiolabel has been widely used by researchers to investigate the fate of inhaled aerosols. The application of two-dimensional (2D) planar gamma scintigraphy and single-photon emission computed tomography (SPECT) to the study of inhaled aerosols is discussed in this review. Information on co-localized anatomy can be derived from other imaging techniques such as krypton ventilation scans and low- and high-resolution X-ray computed tomography (CT). Radionuclide imaging, combined with information on anatomy, is a potentially useful approach when the understanding of regional deposition within the lung is central to research objectives for following disease progression and for the evaluation of therapeutic intervention.
Collapse
Affiliation(s)
- Joy Conway
- Faculty of Health Sciences, University of Southampton, Southampton, UK SO16 6YD.
| | | | | | | |
Collapse
|
21
|
Abstract
Interest in bioequivalence (BE) of inhaled drugs derives largely from the desire to offer generic substitutes to successful drug products. The complexity of aerosol dosage forms renders them difficult to mimic and raises questions regarding definitions of similarities and those properties that must be controlled to guarantee both the quality and the efficacy of the product. Despite a high level of enthusiasm to identify and control desirable properties there is no clear guidance, regulatory or scientific, for the variety of aerosol dosage forms, on practical measures of BE from which products can be developed. As more data on the pharmaceutical and clinical relevance of various techniques, as described in this review, become available, it is likely that a path to the demonstration of BE will become evident. In the meantime, debate on this topic will continue.
Collapse
|
22
|
Fleming J, Bailey DL, Chan HK, Conway J, Kuehl PJ, Laube BL, Newman S. Standardization of Techniques for Using Single-Photon Emission Computed Tomography (SPECT) for Aerosol Deposition Assessment of Orally Inhaled Products. J Aerosol Med Pulm Drug Deliv 2012; 25 Suppl 1:S29-51. [DOI: 10.1089/jamp.2012.1su5] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- John Fleming
- Respiratory Biomedical Research Unit, University Hospital Southampton, NHS Foundation Trust, Southampton, United Kingdom
| | | | - Hak-Kim Chan
- Advanced Drug Delivery Group, The University of Sydney, New South Wales, Australia
| | - Joy Conway
- Respiratory Biomedical Research Unit, University Hospital Southampton, NHS Foundation Trust, Southampton, United Kingdom
- School of Health Sciences, University of Southampton, Southampton, United Kingdom
| | - Philip J. Kuehl
- Lovelace Respiratory Research Institute, Albuquerque, New Mexico
| | - Beth L. Laube
- Johns Hopkins University School of Medicine, Baltimore, Maryland
| | - Stephen Newman
- Scientific Consultant, Hunstanton, Norfolk, United Kingdom
| |
Collapse
|
23
|
The importance of imaging and physiology measurements in assessing the delivery of peripherally targeted aerosolized drugs. Ther Deliv 2012; 3:1329-45. [DOI: 10.4155/tde.12.113] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023] Open
Abstract
Considerable recent effort has been directed towards developing new aerosol formulations and delivery devices that can target drugs to the lung periphery. In order to determine the efficacy of targeted drug therapy, it is essential that the peripheral lung region be adequately assessed. Imaging of the airways structure and pathology has greatly advanced in the last decade and this rate of growth is accelerating as new technologies become available. Lung imaging continues to play an important role in the study of the peripheral airways and, when combined with state-of-the-art lung function measurements and computational modeling, can be a powerful tool for investigating the effects of inhaled medication. This article focuses on recent strategies in imaging and physiological measurements of the lungs that allow the assessment of inhaled medication delivered to the periphery and discusses how these methods may help to further optimize and refine future aerosol delivery technology.
Collapse
|
24
|
Patel B, Gauvin R, Absar S, Gupta V, Gupta N, Nahar K, Khademhosseini A, Ahsan F. Computational and bioengineered lungs as alternatives to whole animal, isolated organ, and cell-based lung models. Am J Physiol Lung Cell Mol Physiol 2012; 303:L733-47. [PMID: 22886505 DOI: 10.1152/ajplung.00076.2012] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023] Open
Abstract
Development of lung models for testing a drug substance or delivery system has been an intensive area of research. However, a model that mimics physiological and anatomical features of human lungs is yet to be established. Although in vitro lung models, developed and fine-tuned over the past few decades, were instrumental for the development of many commercially available drugs, they are suboptimal in reproducing the physiological microenvironment and complex anatomy of human lungs. Similarly, intersubject variability and high costs have been major limitations of using animals in the development and discovery of drugs used in the treatment of respiratory disorders. To address the complexity and limitations associated with in vivo and in vitro models, attempts have been made to develop in silico and tissue-engineered lung models that allow incorporation of various mechanical and biological factors that are otherwise difficult to reproduce in conventional cell or organ-based systems. The in silico models utilize the information obtained from in vitro and in vivo models and apply computational algorithms to incorporate multiple physiological parameters that can affect drug deposition, distribution, and disposition upon administration via the lungs. Bioengineered lungs, on the other hand, exhibit significant promise due to recent advances in stem or progenitor cell technologies. However, bioengineered approaches have met with limited success in terms of development of various components of the human respiratory system. In this review, we summarize the approaches used and advancements made toward the development of in silico and tissue-engineered lung models and discuss potential challenges associated with the development and efficacy of these models.
Collapse
Affiliation(s)
- Brijeshkumar Patel
- Department of Pharmaceutical Sciences, School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, 79106, USA
| | | | | | | | | | | | | | | |
Collapse
|
25
|
Conway J. Lung imaging - two dimensional gamma scintigraphy, SPECT, CT and PET. Adv Drug Deliv Rev 2012; 64:357-68. [PMID: 22310158 DOI: 10.1016/j.addr.2012.01.013] [Citation(s) in RCA: 42] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2011] [Revised: 01/18/2012] [Accepted: 01/24/2012] [Indexed: 12/17/2022]
Abstract
This review will cover the principles of imaging the deposition of inhaled drugs and some of the state-of-the art imaging techniques being used today. Aerosol deposition can be imaged and quantified by the addition of a radiolabel to the aerosol formulation. The subsequent imaging of the inhaled deposition pattern can be acquired by different imaging techniques. Specifically, this review will focus on the use of two-dimensional planar, gamma scintigraphy, SPECT, CT and PET. This review will look at how these imaging techniques are used to investigate the mechanisms of drug delivery in the lung and how the lung anatomy and physiology have the potential to alter therapeutic outcomes.
Collapse
Affiliation(s)
- Joy Conway
- Faculty of Health Sciences, University of Southampton, Southampton General Hospital, UK.
| |
Collapse
|
26
|
Yi D, Naqwi A, Panoskaltsis-Mortari A, Wiedmann TS. Distribution of aerosols in mouse lobes by fluorescent imaging. Int J Pharm 2012; 426:108-115. [PMID: 22306042 DOI: 10.1016/j.ijpharm.2012.01.037] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2011] [Revised: 01/13/2012] [Accepted: 01/15/2012] [Indexed: 11/15/2022]
Abstract
Better methods are needed to quantify the distribution of drug among the airways of the lungs of small animals to facilitate the development of agents that can target specific airways. Mice were exposed to aerosols of aluminum phthalocyanine tetrasulfonic acid (AlPCS) that ranged in concentration and size (0.2-2.8 μm). The trachea and lobes were removed and placed between glass slides, and fluorescent images were obtained at two different compression thicknesses. The intensity, normalized by the area, exposure time, and thickness, was then plotted as a function of compression thickness, from which the concentration and attenuation coefficient were estimated for each lobe and then for each pixel of the image. The latter was then used to generate an image reflective of the concentration. The lobe volume, concentration, and tissue attenuation of AlPCS was consistent among the lobes. The deposition fraction increased with decreasing particle size. The network of lines in the concentration image indicated that connective tissue has a lower concentration. The central airways were clearly evident in the images of mice exposed to the very small and large aerosols. This approach provides a rapid, economical means to obtain high resolution images of mouse lungs from which detailed analysis of the distribution of deposited aerosol particles can be obtained.
Collapse
Affiliation(s)
- Dandan Yi
- Department of Pharmaceutics, University of Minnesota, Minneapolis, MN 55455, United States.
| | - Amir Naqwi
- Powerscope Incorporated, 1313 Fifth Street SE, Minneapolis, MN 55414, United States.
| | | | - Timothy Scott Wiedmann
- Department of Pharmaceutics, University of Minnesota, Minneapolis, MN 55455, United States.
| |
Collapse
|
27
|
King GG. Current and emerging imaging in relation to drug discovery in airways disease. Pulm Pharmacol Ther 2011; 24:497-504. [DOI: 10.1016/j.pupt.2011.07.003] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/22/2011] [Revised: 07/18/2011] [Accepted: 07/20/2011] [Indexed: 11/16/2022]
|
28
|
Zhang J, Wu L, Chan HK, Watanabe W. Formation, characterization, and fate of inhaled drug nanoparticles. Adv Drug Deliv Rev 2011; 63:441-55. [PMID: 21118707 DOI: 10.1016/j.addr.2010.11.002] [Citation(s) in RCA: 118] [Impact Index Per Article: 9.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2010] [Revised: 11/17/2010] [Accepted: 11/21/2010] [Indexed: 12/17/2022]
Abstract
Nanoparticles bring many benefits to pulmonary drug delivery applications, especially for systemic delivery and drugs with poor solubility. They have recently been explored in pressurized metered dose inhaler, nebulizer, and dry powder inhaler applications, mostly in polymeric forms. This article presents a review of processes that have been used to generate pure (non polymeric) drug nanoparticles, methods for characterizing the particles/formulations, their in-vitro and in-vivo performances, and the fate of inhaled nanoparticles.
Collapse
|
29
|
Newman S, Fleming J. Challenges in assessing regional distribution of inhaled drug in the human lungs. Expert Opin Drug Deliv 2011; 8:841-55. [PMID: 21554149 DOI: 10.1517/17425247.2011.577063] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
INTRODUCTION Both the total amount of drug deposited in the lungs (whole lung deposition) and the amount deposited in different lung regions (regional lung deposition) are potentially important factors that determine the safety and efficacy of inhaled drugs. Radionuclide imaging is well established for quantifying the whole lung deposition of inhaled drugs, but the assessment of regional lung deposition is less straightforward, because of the complex nature of the lung anatomy. AREAS COVERED This review describes the challenges and problems associated with quantifying regional lung deposition by the two-dimensional (2D) radionuclide imaging method of gamma scintigraphy, and by the three-dimensional (3D) radionuclide imaging methods of single-photon-emission computed tomography (SPECT) and positron-emission tomography (PET). The advantages and disadvantages of each method for assessing regional lung deposition are discussed. EXPERT OPINION Owing to its 2D nature, gamma scintigraphy provides limited information about regional lung deposition. SPECT provides regional lung deposition data in three dimensions, but usually involves a (99m)Tc radiolabel. PET enables the regional lung deposition of radiolabeled drug molecules to be quantified in three dimensions, but poses the greatest logistical and technical difficulties. Despite their more challenging nature, 3D imaging methods should be considered as an alternative to gamma scintigraphy whenever the determination of regional lung deposition of pharmaceutical aerosols is a major study objective.
Collapse
|
30
|
Scheuch G, Bennett W, Borgström L, Clark A, Dalby R, Dolovich M, Fleming J, Gehr P, Gonda I, O'Callaghan C, Taylor G, Newman S. Deposition, imaging, and clearance: what remains to be done? J Aerosol Med Pulm Drug Deliv 2011; 23 Suppl 2:S39-57. [PMID: 21133799 DOI: 10.1089/jamp.2010.0839] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
Deposition and clearance studies are used during product development and in fundamental research. These studies mostly involve radionuclide imaging, but pharmacokinetic methods are also used to assess the amount of drug absorbed through the lungs, which is closely related to lung deposition. Radionuclide imaging may be two-dimensional (gamma scintigraphy or planar imaging), or three-dimensional (single photon emission computed tomography and positron emission tomography). In October 2009, a group of scientists met at the "Thousand Years of Pharmaceutical Aerosols" conference in Reykjavik, Iceland, to discuss future research in key areas of pulmonary drug delivery. This article reports the session on "Deposition, imaging and clearance." The objective was partly to review our current understanding, but more importantly to assess "what remains to be done?" A need to standardize methodology and provide a regulatory framework by which data from radionuclide imaging methods could be compared between centers and used in the drug approval process was recognized. There is also a requirement for novel radiolabeling methods that are more representative of production processes for dry powder inhalers and pressurized metered dose inhalers. A need was identified for studies to aid our understanding of the relationship between clinical effects and regional deposition patterns of inhaled drugs. A robust methodology to assess clearance from small conducting airways should be developed, as a potential biomarker for therapies in cystic fibrosis and other diseases. The mechanisms by which inhaled nanoparticles are removed from the lungs, and the factors on which their removal depends, require further investigation. Last, and by no means least, we need a better understanding of patient-related factors, including how to reduce the variability in pulmonary drug delivery, in order to improve the precision of deposition and clearance measurements.
Collapse
|
31
|
King GG, Harris B, Mahadev S. V/Q SPECT: utility for investigation of pulmonary physiology. Semin Nucl Med 2011; 40:467-73. [PMID: 20920636 DOI: 10.1053/j.semnuclmed.2010.07.006] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
Single-photon emission computed tomography (SPECT) is being increasingly used as a tool in respiratory research, in particular ventilation SPECT. Much of the basic understanding of pulmonary physiology has been derived from inhaled radioactive inert gases because, as the lung behaves in an asymmetric manner, the nature of regional differences in ventilation is ideally studied with the use of imaging. It is well known to clinicians that ventilation is patchy in patients who have airways disease. However, the relevance to the disease mechanisms itself only started to be studied with the use of 3-dimensional imaging and with advances in quantitative image analysis. The measurements of both ventilation distribution and nonventilation (airway closure) have become very topical in the study of asthma, and accurate quantification of those parameters is of relevance to disease mechanisms. In chronic obstructive pulmonary disease, the drive is towards better characterization of disease groups ("phenotypes") and, again, description of ventilation patterns may prove to be useful. This is a review, therefore, on pulmonary SPECT imaging in respiratory research which includes a focus on methodology in relation to respiratory physiology. There has been relatively little published in this area but there is great potential for advances in the understanding of airways disease to be gained from SPECT imaging.
Collapse
Affiliation(s)
- Gregory G King
- Woolcock Institute of Medical Research, Sydney, NSW, Australia; University of Sydney, Sydney, NSW, Australia.
| | | | | |
Collapse
|
32
|
Forbes B, Asgharian B, Dailey LA, Ferguson D, Gerde P, Gumbleton M, Gustavsson L, Hardy C, Hassall D, Jones R, Lock R, Maas J, McGovern T, Pitcairn GR, Somers G, Wolff RK. Challenges in inhaled product development and opportunities for open innovation. Adv Drug Deliv Rev 2011; 63:69-87. [PMID: 21144875 DOI: 10.1016/j.addr.2010.11.004] [Citation(s) in RCA: 83] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2010] [Revised: 11/19/2010] [Accepted: 11/25/2010] [Indexed: 11/26/2022]
Abstract
Dosimetry, safety and the efficacy of drugs in the lungs are critical factors in the development of inhaled medicines. This article considers the challenges in each of these areas with reference to current industry practices for developing inhaled products, and suggests collaborative scientific approaches to address these challenges. The portfolio of molecules requiring delivery by inhalation has expanded rapidly to include novel drugs for lung disease, combination therapies, biopharmaceuticals and candidates for systemic delivery via the lung. For these drugs to be developed as inhaled medicines, a better understanding of their fate in the lungs and how this might be modified is required. Harmonized approaches based on 'best practice' are advocated for dosimetry and safety studies; this would provide coherent data to help product developers and regulatory agencies differentiate new inhaled drug products. To date, there are limited reports describing full temporal relationships between pharmacokinetic (PK) and pharmacodynamic (PD) measurements. A better understanding of pulmonary PK and PK/PD relationships would help mitigate the risk of not engaging successfully or persistently with the drug target as well as identifying the potential for drug accumulation in the lung or excessive systemic exposure. Recommendations are made for (i) better industry-academia-regulatory co-operation, (ii) sharing of pre-competitive data, and (iii) open innovation through collaborative research in key topics such as lung deposition, drug solubility and dissolution in lung fluid, adaptive responses in safety studies, biomarker development and validation, the role of transporters in pulmonary drug disposition, target localisation within the lung and the determinants of local efficacy following inhaled drug administration.
Collapse
|
33
|
Measurement of the distribution of aerosols among mouse lobes by fluorescent imaging. Anal Biochem 2010; 403:88-93. [PMID: 20382107 DOI: 10.1016/j.ab.2010.04.005] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2010] [Revised: 03/29/2010] [Accepted: 04/05/2010] [Indexed: 11/23/2022]
Abstract
Lung samples were prepared to investigate the perturbing effects of light absorption for quantifying the fluorescence signal of aluminum phthalocyanine tetrasulfonic acid (AlPCS). Standard solutions of known concentration and depth were imaged with different exposure times and analyzed. The intensity was found to be a linear function of concentration, depth, exposure time, and area. Mice were exposed to an aerosol of AlPCS with a mass median aerodynamic diameter of 390 nm and geometric standard deviation of 1.8. Images of intact lung lobes and lung homogenates were obtained and then analyzed to allow quantifying the concentration of AlPCS among the lung lobes and trachea. For the distribution of aerosols, the results indicate that the concentration was uniform among the different lobes. Combining the quantitative analysis of the concentration with image analysis of the area/thickness, the mass deposited in each lobe was readily determined. This approach provides a quantitative means to determine the selectivity of drug delivery to mouse lower respiratory tract.
Collapse
|
34
|
Abstract
Abstract
Objectives
This review focuses on the key findings and developments in the rapidly expanding research area of pharmaceutical aerosol electrostatics.
Key findings
Data from limited in-vivo and computational studies suggest that charges may potentially affect particle deposition in the airways. Charging occurs naturally in the absence of electric fields through triboelectrification, that is contact or friction for solids and flowing or spraying for liquids. Thus, particles and droplets emitted from pulmonary drug delivery devices (dry powder inhalers, metered dose inhalers with or without spacers, and nebulisers) are inherently charged. Apparatus with various operation principles have been employed in the measurement of pharmaceutical charges. Aerosol charges are dependent on many physicochemical parameters, such as formulation composition, device construction, relative humidity and solid-state properties. In some devices, electrification has been purposefully applied to facilitate powder dispersion and liquid atomisation.
Summary
Currently, there are no regulatory requirements on characterising electrostatic properties of inhalation aerosols. As research in this area progresses, the new knowledge gained may become valuable for the development and regulation of inhalation aerosol products.
Collapse
Affiliation(s)
- Philip Chi Lip Kwok
- Advanced Drug Delivery Group, Faculty of Pharmacy, The University of Sydney, New South Wales, Australia
| | - Hak-Kim Chan
- Advanced Drug Delivery Group, Faculty of Pharmacy, The University of Sydney, New South Wales, Australia
| |
Collapse
|
35
|
Devillier P, Naline E, Dubus JC. Pourquoi et comment mesurer et optimiser le dépôt pulmonaire des traitements inhalés ? Rev Mal Respir 2009; 26:1127-37. [DOI: 10.1016/s0761-8425(09)73539-9] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
36
|
Möller W, Felten K, Meyer G, Meyer P, Seitz J, Kreyling WG. Corrections in Dose Assessment of99mTc Radiolabeled Aerosol Particles Targeted to Central Human Airways Using Planar Gamma Camera Imaging. J Aerosol Med Pulm Drug Deliv 2009; 22:45-54. [DOI: 10.1089/jamp.2007.0664] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
Affiliation(s)
- Winfried Möller
- Helmholtz Zentrum München–German Research Center for Environmental Health, Clinical Cooperation Group Inflammatory Lung Diseases, Institute for Inhalation Biology, and Focus Network Aerosols and Health, Gauting and Neuherberg, Germany
| | - Kathrin Felten
- Helmholtz Zentrum München–German Research Center for Environmental Health, Clinical Cooperation Group Inflammatory Lung Diseases, Institute for Inhalation Biology, and Focus Network Aerosols and Health, Gauting and Neuherberg, Germany
| | - Gabriele Meyer
- Asklepios Hospital for Respiratory Diseases, Gauting, Germany
| | - Peter Meyer
- Helmholtz Zentrum München–German Research Center for Environmental Health, Clinical Cooperation Group Inflammatory Lung Diseases, Institute for Inhalation Biology, and Focus Network Aerosols and Health, Gauting and Neuherberg, Germany
- Asklepios Hospital for Respiratory Diseases, Gauting, Germany
| | | | - Wolfgang G. Kreyling
- Helmholtz Zentrum München–German Research Center for Environmental Health, Clinical Cooperation Group Inflammatory Lung Diseases, Institute for Inhalation Biology, and Focus Network Aerosols and Health, Gauting and Neuherberg, Germany
| |
Collapse
|
37
|
Finlay WH, Martin AR. Recent advances in predictive understanding of respiratory tract deposition. J Aerosol Med Pulm Drug Deliv 2008; 21:189-206. [PMID: 18518795 DOI: 10.1089/jamp.2007.0645] [Citation(s) in RCA: 59] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Accurate prediction of respiratory tract deposition is important in gauging the health risks of ambient bioaerosols and environmental aerosols, as well as in developing pharmaceutical aerosols for drug delivery. The present article highlights recent advances in the prediction of total, extrathoracic, and lung deposition fractions of inhaled aerosols over a broad range of parameters for both oral and nasal breathing. These advances build on recent data from in vivo and in vitro studies that have benefited from recent improvements in high-resolution imaging, rapid prototyping, and computational simulation abilities that have significantly enhanced the current understanding of respiratory tract deposition. It is anticipated that the relatively simple equations for predicting total or whole lung deposition that follow from the recent work discussed herein will allow for improved correlation between respiratory tract deposition and a wide range of health outcomes.
Collapse
|
38
|
Newman SP, Chan HK. In vitro/in vivo comparisons in pulmonary drug delivery. J Aerosol Med Pulm Drug Deliv 2008; 21:77-84. [PMID: 18518834 DOI: 10.1089/jamp.2007.0643] [Citation(s) in RCA: 98] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Establishing clear relationships between in vitro and in vivo data for inhaled drug products is an important goal. In vitro aerodynamic particle size distributions (APSDs) are expected to have some predictive power not only for drug deposition, but also for clinical effects. APSD data obtained by cascade impaction have been compared with lung deposition data measured in gamma scintigraphy studies. Whole-lung deposition correlated significantly with fine particle fraction (FPF) across a range of inhaler devices. FPF, defined in terms of aerosol <5.8 microm or <6.8 microm diameter, systematically overestimated lung deposition for virtually all inhalers. Lung deposition showed closer numerical equivalence to the percentage of the aerosol dose smaller than 3 microm diameter. Correlations exist between APSD data and whole-lung deposition, which may allow the greater use of APSD data for comparing inhaler devices. Agreement between in vitro and in vivo data may be improved by measuring APSD in ways that more closely mimic clinical use, including the use of impactor inlets that simulate the human upper airway anatomy. At the present time there are few published data that relate APSD to the clinical response of inhaled drugs in an unambiguous way.
Collapse
|
39
|
Möller W, Meyer G, Kreyling WG. Advances in lung imaging techniques for the treatment of respiratory disease. ACTA ACUST UNITED AC 2008. [DOI: 10.1016/j.ddstr.2008.06.002] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
40
|
|
41
|
Petersson J, Sánchez-Crespo A, Larsson SA, Mure M. Physiological imaging of the lung: single-photon-emission computed tomography (SPECT). J Appl Physiol (1985) 2007; 102:468-76. [PMID: 16990505 DOI: 10.1152/japplphysiol.00732.2006] [Citation(s) in RCA: 99] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Emission tomography provides three-dimensional, quantitative images of the distribution of radiotracers used to mark physiological, metabolic, or pathological processes. Quantitative single photon emission computed tomography (SPECT) requires correction for the image-degrading effects due to photon attenuation and scatter. Phantom experiments have shown that radioactive concentrations can be assessed within some percentage of the true value when relevant corrections are applied. SPECT is widely spread, and radiotracers are available that are easy to use and comparably inexpensive. Compared with other methods, SPECT suffers from a lower spatial resolution, and the time required for image acquisition is longer than for some alternative methods. In contrast to some other methods, SPECT allows simultaneous imaging of more than one process, e.g., both regional blood flow and ventilation, for the whole lung. SPECT has been used to explore the influence of posture and clinical interventions on the spatial distribution of lung blood flow and ventilation. Lung blood flow is typically imaged using macroaggregates of albumin. Both radioactive gases and particulate aerosols labeled with radioactivity have been used for imaging of regional ventilation. However, all radiotracers are not equally suited for quantitative measurements; all have specific advantages and limitations. With SPECT, both blood flow and ventilation can be marked with radiotracers that remain fixed in the lung tissue, which allows tracer administration during conditions different from those at image registration. All SPECT methods have specific features that result from the used radiotracer, the manner in which it is administered, and how images are registered and analyzed.
Collapse
Affiliation(s)
- Johan Petersson
- Department of Anesthesiology and Intensive Care, Karolinska University Hospital, Solna, 171 76 Stockholm, Sweden.
| | | | | | | |
Collapse
|